Gilbert R Thompson

List of Publications by Year
in descending order

41 papers	2,003 citations	361413 20 h-index	276875 41 g-index
43 all docs	43 docs citations	43 times ranked	1420 citing authors

#	Article	IF	Citations
1	The scientific basis and future of lipoprotein apheresis. Therapeutic Apheresis and Dialysis, 2022, 26, 32-36.	0.9	16
2	FH through the retrospectoscope. Journal of Lipid Research, 2021, 62, 100036.	4.2	5
3	Use of apheresis in the age of new therapies for familial hypercholesterolaemia. Current Opinion in Lipidology, 2021, 32, 363-369.	2.7	4
4	PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 76, 143-145.	2.8	6
5	Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989â€“2017. Atherosclerosis, 2019, 290, 44-51.	0.8	25
6	Current Role of Lipoprotein Apheresis. Current Atherosclerosis Reports, 2019, 21, 26.	4.8	63
7	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. European Heart Journal, 2018, 39, 1162-1168.	2.2	81
8	Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans. Atherosclerosis, 2018, 276, 148-154.	0.8	6
9	Limitations of cholesterol lowering with PCSK9 inhibitors. Lancet Diabetes and Endocrinology,the, 2017, 5, 241-243.	11.4	4
10	HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis, 2016, 255, 128-139.	0.8	76
11	Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances. Current Atherosclerosis Reports, 2015, 17, 465.	4.8	53
12	Obituary of Dr N.B. Myant. Atherosclerosis, 2015, 240, 437-438.	0.8	0
13	Managing homozygous familial hypercholesterolaemia from cradle to grave. Atherosclerosis Supplements, 2015, 18, 16-20.	1.2	18
14	Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. Atherosclerosis, 2015, 243, 328-333.	0.8	37
15	Lipoprotein(a): the underestimated cardiovascular risk factor. Heart, 2014, 100, 534-535.	2.9	14
16	The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atherosclerosis Supplements, 2013, 14, 67-70.	1.2	56
17	Lipoprotein apheresis for the treatment of familial hypercholesterolemia. Clinical Lipidology, 2013, 8, 573-586.	0.4	6
18	Lipoprotein apheresis. Current Opinion in Lipidology, 2010, 21, 487-491.	2.7	44

#	Article	IF	Citations
19	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Current Opinion in Lipidology, 2010, 21, 492-498.	2.7	95
20	Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis, 2010, 208, 317-321.	0.8	115
21	History and Development of Plant Sterol and Stanol Esters for Cholesterol-Lowering Purposes. American Journal of Cardiology, 2005, 96, 3-9.	1.6	122
22	Comparison of Efficacy of Plant Stanol Ester and Sterol Ester: Short-Term and Longer-Term Studies. American Journal of Cardiology, 2005, 96, 29-36.	1.6	67
23	Additive Effects of Plant Sterol and Stanol Esters to Statin Therapy. American Journal of Cardiology, 2005, 96, 37-39.	1.6	27
24	Management of dyslipidaemia. Heart, 2004, 90, 949-955.	2.9	24
25	Current management of severe homozygous hypercholesterolaemias. Current Opinion in Lipidology, 2004, 15, 413-422.	2.7	88
26	LDL apheresis. Atherosclerosis, 2003, 167, 1-13.	0.8	173
27	Screening relatives of patients with premature coronary heart disease. British Heart Journal, 2002, 87, 390-394.	2.1	8
28	Goals of statin therapy: Three viewpoints. Current Atherosclerosis Reports, 2002, 4, 26-33.	4.8	5
29	Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 832-837.	2.4	58
30	Novel lipid-regulating drugs. Expert Opinion on Investigational Drugs, 2000, 9, 2619-2628.	4.1	24
31	New prospects for lipid-lowering drugs. Expert Opinion on Investigational Drugs, 1998, 7, 715-727.	4.1	4
32	The Effect of Cholesterol Reduction with Fluvastatin on Aortic Compliance, Coronary Calcification and Carotid Intimal-Medial Thickness: A Pilot Study. European Journal of Cardiovascular Prevention and Rehabilitation, 1998, 5, 1-10.	2.8	9
33	The Role of Low Density Lipoprotein Apheresis in the Treatment of Familial Hypercholesterolemia. Therapeutic Apheresis and Dialysis, 1997, 1, 13-16.	0.6	9
34	The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 61-67.	1.5	46
35	Treatment of hyperlipidaemia. Clinical Endocrinology, 1993, 38, 337-342.	2.4	1
36	Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia. New England Journal of Medicine, 1990, 322, 1494-1499.	27.0	582

#	Article	IF	Citations
37	Normal and Pathological Lipoprotein Metabolism. Drugs, 1988, 36, 51-54.	10.9	10
38	Clinical pharmacology: New hopes for the treatment of coronary heart disease. Nature, 1986, 324, 412-412.	27.8	0
39	Antherosclerosis and hyperlipidaemia: Genetic polymorphism and plasma lipoproteins. Nature, 1983, 301, 658-658.	27.8	5
40	The Lipid Hypothesis. Acta Medica Scandinavica, 1980, 208, 341-342.	0.0	1
41	Plasma Lipid and Lipoprotein Abnormalities in Patients with Malabsorption. Clinical Science and Molecular Medicine, 1973, 45, 583-592.	0.8	14